CDE与山东省药监局达成战略合作 共同提升药品审评能力

2017-06-23 佚名 医药魔方

为加快推进药品审评审批制度改革,促进国家总局及省局技术审评优势互补,共同推进药品技术审评能力建设,5月26日,国家食品药品监督管理总局药审中心与山东省食品药品监督管理局签署战略合作协议。总局副局长孙咸泽出席签字仪式并讲话。

为加快推进药品审评审批制度改革,促进国家总局及省局技术审评优势互补,共同推进药品技术审评能力建设,5月26日,国家食品药品监督管理总局药审中心与山东省食品药品监督管理局签署战略合作协议。总局副局长孙咸泽出席签字仪式并讲话。孙咸泽指出,双方签署的合作协议是全国首个省级食品药品监管局与药审中心签署的战略合作协议,对药品审评体系构建具有重要开创性、探索性意义。

一是优势互补。药审中心有技术优势,“有专业”,省局熟悉基层监管,“接地气”,两者结合既可以更好地服务山东省内医药产业的健康发展,又可以为审评改革提供实践基础。

二是提高能力。审评中心近两年大规模招聘人才,其中相当大一部分是应届毕业生,可以利用山东局的培训平台、实训基地,让他们去看去学,尽快形成审评能力。

三是培育队伍。在药审中心挂职工作的山东局的审评人才队伍是审评体系建设的重要组成部分,继续发挥作用,为审评审批改革贡献力量。根据协议,药审中心将与山东省局围绕平台建设和能力提升开展多层次合作,实现优势互补、资源共享、互惠共赢。在平台建设方面,双方将共同加强药品数据管理平台建设,建设审评员实训基地,加强审评员对新药研发、药品生产质量管理和现场核查等一线工作情况的了解,提高审评实践能力。

在人员交流方面,山东省局将选派20-40人的审评团队到药审中心挂职,参与技术审评培训,并承担部分审评任务;药审中心也将根据需要,选派年轻干部到山东省局学习锻炼,了解基层工作情况,增强解决实际问题的能力,对山东省药品技术审评给予业务支持。

此外,药审中心将支持山东省药品审评制度改革工作,推动山东省贯彻落实国家关于药品审评制度改革的各项决策部署,支持相关培训工作,山东省局还将为药审中心药品审评部分技术指导原则的制定、修订提供支持和帮助。为加强联系推进合作,药审中心和山东省局将建立战略合作领导小组,每年召开会议,研究合作中的重大事项,并建立联络人定期沟通机制,派专人促进合作事宜的落实。

双方负责人均表示,此番合作将有利于加强审评队伍建设和能力建设,建立更加科学、规范、高效的药品审评审批管理体系,更好地实现国家审评机构对基层药监机构的技术支撑和服务。

签字仪式结束后,孙咸泽赴山东省药品审评认证中心、山东省食品药品检验研究院、山东省药学科学院、山东宏济堂制药集团股份有限公司进行了调研。药审中心主任许嘉齐、山东省局局长马越南、中国食品药品检定研究院院长李波、药审中心党委副书记兼纪委书记严文君、总局药化注册管理司综合处处长李江宁等出席签字仪式并陪同调研。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-25 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-24 189****7206

    学习了受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908089, encodeId=3a36190808924, content=<a href='/topic/show?id=96334e74810' target=_blank style='color:#2F92EE;'>#山东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47748, encryptionId=96334e74810, topicName=山东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 25 16:35:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301556, encodeId=7e92130155655, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478207, encodeId=ff0f14e820782, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570425, encodeId=709915e042580, content=<a href='/topic/show?id=98a18e3969d' target=_blank style='color:#2F92EE;'>#药品审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87396, encryptionId=98a18e3969d, topicName=药品审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b15654332, createdName=qingrejiedu, createdTime=Sun Jun 25 10:35:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214690, encodeId=51c72146908b, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Jun 24 07:46:30 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214444, encodeId=cbf52144448a, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Fri Jun 23 19:41:04 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-23 thlabcde

    好东西学习了!

    0

相关资讯

我国药品审评审批制度改革显成效,基本消除药品注册申请积压

国家食品药品监督管理总局局长毕井泉受国务院委托,向全国人大常委会报告药品管理工作情况时表示,我国目前基本消除了药品注册申请积压,等待审评的药品注册申请已由2015年高峰时的22000件降至6000件。化学药和疫苗临床试验申请、中药各类注册申请已实现按时限审评。毕井泉介绍,为解决长期以来形成的药品注册积压、新药上市慢、制药行业低水平重复、创新能力不足等突出问题,2015年8月国务院印发《关于改革药品

解析!2016度药品审评报告:两升两降、四大亮点(附全文)

自2015年8月国务院下发《关于改革药品医疗器械审评审批制度的意见》(44号文)之后,我国开启了药品审评审批制度上全方位的改革,而CFDA药品审评中心的工作也更受瞩目。

进口新药开“绿色通道”,临床通过可优先在国内上市

尽管在药品审评审批体制机制上已经持续改革,但食药监这次放出的“大招”还是让业界有些诧异。日前,食药监总局发布进口药品注册管理有关决定,拟准许境外未注册或尚未进入临床实验的药品可在国内进行国际多中心临床实验,已经在国内完成临床实验之后,可直接提出药品上市注册申请。

卫计委:18个重大新药创制优先药品审评名单

为加快重大新药创制科技重大专项(以下简称“新药专项”)创新成果产出进程,根据有关文件规定和专家评审遴选建议,拟推荐法米替尼等18个专项支持的药物品种为优先审评品种。 现将拟推荐的品种予以公示。公示时间为2015年1月13日至2015年1月22日。如有异议,请实名反馈至我办。 联系电话:010-68792529 传    真:010-68792226 邮&nbs